Transportability of Comparative Effectiveness and Cost-Effectiveness between Countries  by Briggs, Andrew
Transportability of Comparative Effectiveness and
Cost-Effectiveness between Countries
Andrew Briggs, BA, MSc, DPhil
Public Health & Health Policy, University of Glasgow, Glasgow, UK
Keywords: QALY, regional estimates, sub-group analysis, transferability.
Introduction
Most clinical trials performed today are multicenter and many
are multinational. The inclusion of multiple centers and countries
usually allows the enrollment of a larger sample size in a shorter
period of time, which affords greater statistical power. Other
advantages include the perception of greater generalizability and
the opportunity for the sponsor, in the case of a drug trial, to use
the results for registration in more than one country. At the same
time, this design poses a number of challenges for interpreting the
resulting cost-effectiveness ratio(s). One of these challenges is
whether the data required for cost-effectiveness analysis—and
thus the cost-effectiveness recommendations—can be assumed to
be equivalent across the different countries.
In this article, a brief overview of the literature on economic
analysis of multinational studies is presented. The ﬁrst section
relates to the background on the transferability of economic data
and the second section discusses the results of a consensus con-
ference on economic analysis of multinational trials. The third
section considers the two main statistical approaches that have
been advocated for handling the analysis of multinational
data—ﬁxed effect and random effect modeling methods—plus a
third approach that has only recently been employed in the
literature based on modeling the components of the cost-
effectiveness calculus. This approach is then illustrated using the
results of the recently published cost-effectiveness analysis of the
TOwards a Revolution in COPD Health (TORCH) trial [1]. A
ﬁnal section offers some conclusions for the use of such methods
in comparative effectiveness and cost-effectiveness studies.
Background to theTransferability of
Economic Data
In an early contribution to the literature, O’Brien [2] identiﬁed
six threats to the transferability of data for economic analysis for
questions of whether treatments that are cost-effective in one
country might not necessarily be cost-effective in another. These
six threats are also useful to consider in the context of multina-
tional clinical trials.
Demography and Epidemiology of Disease
The underlying premise of a multinational clinical trial is that the
treatment effect on the underlying biological process is constant
across countries. Nevertheless, differences in demography and
epidemiology of disease between countries may threaten this
assumption, particularly with respect to the absolute beneﬁt of
treatment in different countries. The treatment effect in most
clinical trials is often a relative measure, such as hazard ratios,
relative risks, or odd ratios. In such cases, it is likely that the most
it will be appropriate to assume is a constant relative treatment
effect across countries, especially when baseline epidemiology/
demography differs [3]. Even this assumption may not be sup-
portable. Although large numbers of studies claim to rule out
country by treatment interactions for the clinical ﬁndings, the
power of these tests is usually very limited. The conclusion of no
interaction may be a misrepresentation of the ﬁnding that there is
an absence of evidence of a difference as an indication that there
is evidence of an absence of a difference.
Clinical Practice and Conventions
In a clinical trial, the differences in clinical practice and conven-
tions between countries may be limited by the trial’s protocol.
Nevertheless, there is the potential for differences in provision of
“usual care” (as opposed to the treatments under evaluation) to
impact the comparison between countries. For example, the rate
of surgical intervention, compared to medical management, is
known to be higher in the United States than in many other
health systems [4,5]. Country-speciﬁc differences in lengths of
stay in the hospital have also been observed in some trials [6].
Incentives and Regulations for Health-Care Providers
Different countries will have different incentives and regulations
which will result in practice variations between countries. These
in turn may result in different levels of resource use across dif-
ferent categories of care.
Relative Price Levels
Absolute price levels clearly differ between countries, but these
can be accounted for directly in the valuation of the trial’s
resource use. Country-speciﬁc relative price differences between
different categories of resource use, on the other hand, are poten-
tially more problematic for multinational studies. Economic
theory suggests that differences in relative prices will result in
substitution from relatively more expensive resources to rela-
tively cheaper ones. Therefore, differences in relative prices
between countries should lead to different practice patterns.
Consumer (Patient) Preferences
Quality of life measures that are used in the calculation of quality-
adjusted life-years (QALYs) are based upon individual prefer-
ences. There is no reason to suppose that these preferences are not
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culturally dependent such that we might expect differences to be
observed between countries. At the same time, use of pre-scored
instruments, such as the EuroQol 5-D or theHealth Utilities Index
2 or 3 to assess preferences will tend to mask such differences.
Opportunity Costs of Resources
Different countries will have different levels of ability to pay for
improved health outcomes. What is considered cost-effective in a
health system in North America or Western Europe may not be
considered affordable in South America or Eastern Europe. This
fundamentally limits the usefulness of an overall conclusion of
any cost-effectiveness analysis of a trial, but does not invalidate
the cost-effectiveness results.
The ﬁrst ﬁve of these six threats to transferability of economic
data provide reasons why we might be concerned with making a
single estimate of cost-effectiveness across all countries. Yet, as
was argued in the Introduction, the rationale for multinational
clinical trials is usually related to obtaining a large study with
power to detect treatment effects. The fundamental problem,
therefore, relates to whether data are pooled to maximize power
or split to maximize the credibility of the economic analysis in
each individual country.
Results from a ConsensusWorkshop
A taxonomy of different approaches to economic appraisal in
multinational clinical trials was recently developed as part of a
workshop to explore whether it was possible to gain consensus on
how to analyze such trials [7]. The categorization relates to the
intersection between three factors: whether themeasure of clinical
effectiveness data was pooled across all countries or split by
country; whether the measure of resource use data was obtained
by pooling across all countries or by splitting by country; and
whether service use was valued by use of unit costs from multiple
countries or by use of a single set of unit costs from one country.
The ﬁrst two factors are combined to deﬁne a fully pooled analysis
(clinical outcomes and resource use averaged across all countries);
a fully split analysis (clinical outcomes and resource use from an
individual country or from individual countries); or a partially
split analysis (clinical effect averaged across all countries and
resource use from an individual country or from individual coun-
tries) (the fourth option, clinical effect from an individual country
and resource use averaged across all countries, was not considered
in the article, presumably because it was felt to be an unlikely
approach in practice). For each of these three broad categories,
two subcategories were created to distinguish the approach used
for costing resource use: a study used “one country” costing if it
used costs (prices) from a single country; it used “multi-country”
costing if it used costs from multiple countries.
The authors then reviewed 18 economic analyses conducted
alongside clinical trials published in the cardiology ﬁeld and
found that the fully pooled approach has been the most prevalent
approach to date, with half of all the studies presenting their
analysis in this way, although only two used multicountry
costing. Fully split analyses are much less common, with only
two studies presenting this approach. The second most common
approach was to present partially split, one country costing
results. Although some may consider that this method provides
an insight into the results for a single country, and while its
adoption may satisfy decision-makers who are located in these
single countries, there is no evidence that analyses of this type
provide information about the cost-effectiveness of the therapy in
any one of the individual countries that participated in the trial.
Analytical Approaches to Analyzing
Multinational Trials
Fixed Effect Approaches
One of the earliest attempts to address the statistical analysis of
multinational clinical trials for cost-effectiveness analysis was
presented by Willke and colleagues [8]. They examined how
clinical and economic outcomes interact using data from a mul-
tinational clinical trial of treatment of subarachnoid hemorrhage.
Using a series of regression analyses, they developed a novel
approach that explored the treatment by country interactions in
both outcome (death) and cost, and which allowed the treatment
effect on cost to be estimated independently of the outcome effect
on cost. Use of a fully pooled analysis with multicountry costing
produced just a single cost-effectiveness ratio for the whole trial.
Use of a fully pooled analysis with one country costing produced
ratios for each country that had very little variability between
them. Partial splitting with multicountry costing provided a
much greater spread, but the widest variation came from the fully
split, multicountry costing analysis.
The increasing spread of results as the data are more widely
split is entirely consistent with expectations. The smaller sample
sizes involved in the split analyses will increase variability. The
key question is to what extent this variability is related to
random error or to what extent it reﬂects systematic differences
in the cost-effectiveness between countries because of the sorts of
factors discussed previously.
In a more recent contribution, Cook and colleagues [9] pro-
posed the use of standard tests of heterogeneity in the compari-
son of cost and effects [10] to inform decisions about whether it
is appropriate to pool economic data across countries. They
outline methods based both on incremental net beneﬁt (INB) and
the angular transformation of the incremental cost-effectiveness
ratio and illustrate them by use of the 4S study of cholesterol
reduction with simvastatin [11,12]. The results of their INB
analysis for the countries of Denmark, Finland, Iceland, Norway,
and Sweden were presented for a willingness to pay threshold of
$75,000 per additional survivor.
The results show that there is some variability when country-
speciﬁc subsets are analyzed. Positive net-beneﬁt is observed for
Denmark, Finland and Sweden, whereas negative net-beneﬁts are
observed in Norway and Iceland. Nevertheless, all of the conﬁ-
dence limits overlap zero and tests for both quantitative and
qualitative interactions are insigniﬁcant. The authors suggest that
in the absence of strong evidence of heterogeneity, it is appropri-
ate to consider pooling these data and the overall pooled estimate
(ignoring country) is clearly much more precise with a much
tighter conﬁdence interval (which nevertheless still overlaps zero
net-beneﬁt).
The authors are careful to point out that these tests often suffer
from lowpower. This is perhaps unsurprising given that part of the
rationale for multinational trials is to achieve sufﬁcient power
overall on the main clinical end point. The authors suggest that
evidence of a country-by-treatment interaction is likely to provide
an argument against pooling the data, but that absence of evidence
should not necessarily be interpreted as a rationale to pool.
Given the relative similarity of the Scandinavian countries
and their health systems, the lack of heterogeneity in this case is
not unexpected. For multinational trials covering a broader
range of countries, evidence of heterogeneity may be more likely.
Random Effects Approaches
The potential problem with the ﬁxed effect approaches identiﬁed
previously is that they require a choice to be made between
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pooling or splitting. Although when splitting the data, random
error is important, systematic differences between countries are
also likely to be important. Random effects models offer the
potential to estimate systematic differences between countries,
while simultaneously adjusting for their expected random error
associated with splitting the data. In this regard, they offer some-
thing of a statistical middle ground between a fully split analysis
and a fully pooled analysis, while reﬂecting the natural hierarchy
in the data structure of subjects belonging to countries or regions.
Random effects modeling was identiﬁed as a promising method
at the consensus conference discussed previously and there have
recently been a number of published examples of its application
[13–15].
Statistical Modeling of Cost-Effectiveness Components
An alternative approach than the two approaches outlined previ-
ously is to consider separate statistical modeling of the compo-
nents of cost and effect. This sort of modeling is common in
decision analysis. Indeed, when ﬁrst introducing decision analysis-
based cost-effectiveness to a clinical audience, Weinstein and
Stason emphasized that cost and effect differences are made up of
components. These components relate to the cost of treatment, the
effect of treatment on length of life and associated costs, the effect
of treatment on the morbidity of the disease and the consequent
effects on quality of life and cost, and the effect of treatment side
effects on quality of life and cost [16]. This sort of approach offers
a number of advantages over the traditional approach to cost-
effectiveness analysis based on analyzing the trial directly via the
mean cost and effect in each arm. For example, it is possible to
choose the appropriate statistical model for component, with
explanatory variables that vary by component, and with different
scales for different components. It can be easier to incorporate
external evidence where required (for example, quality of life
weights attached to events) and an analysis based on components
may form a more logical basis for extrapolation.
One of the consequences of allowing different scales of mea-
surement and different explanatory factors (including treatment
effects) is that heterogeneity is directly estimated and this can
lead to a form of sub-group analysis that is not based on split-
ting the data and which may therefore avoid some of the prob-
lems associated with standard approaches to sub-group analysis.
For example, in their cost-effectiveness analysis of the TORCH
study, Briggs and colleagues [1] separately modeled study treat-
ment cost, other medical costs, health related quality of life
(HRQoL) and survival including an assessment of treatment by
country interaction terms to estimate jurisdiction-speciﬁc cost-
effectiveness from this multinational study. Regional cost-
effectiveness results were estimated from a combination of
signiﬁcant treatment by region interactions on treatment cost,
with multiplicative models with main effects only for survival
and other medical costs. The resulting region-speciﬁc estimates
had tighter conﬁdence intervals than an analysis based on split-
ting the trial into separate regions, while still allowing for some
regional variation based on different baseline characteristics.
The results of this analysis are shown in Figure 1.
Of course, these potential advantages come at the price of the
assumptions that are introduced. The conventional cost-
effectiveness approach to trial-based evaluation requires little in
the way of assumptions and that is its principal strength. The
alternative approach based on statistical modeling of clinical
events, or components of cost-effectiveness, introduces addi-
tional assumptions to the analysis. The validity of the results is
therefore conditional on those assumptions holding. Neverthe-
less, the assumptions employed are often the “natural assump-
tions” that in any case underpin the clinical analysis of events
from a trial. Furthermore, any concerns over potential manipu-
lation for the results can be guarded against by fully specifying
the analysis plan for the health economic analysis. Although it
may be too early to be sure whether such event-based analysis
will become the new standard, it offers sufﬁcient advantages that
it should be considered seriously by all those embarking on
trial-based economic evaluation studies.
Closing Remarks
In studying comparative effectiveness (and cost-effectiveness) in
multinational studies, it is important to acknowledge the poten-
tial for the results of the study to vary across different countries/
geographic regions. Simply pooling results across a multinational
trial without regard for this potential risks inappropriate
decision-making in at least some of the jurisdictions covered by
the trial. It was argued that an analysis based on separate com-
ponents making up the effectiveness (and cost-effectiveness) cal-
culus offers a robust way forward that can avoid splitting the
data. The utility of QALYs has long been recognized in the health
economics community as a measure that can bring together
different aspects of treatment effect on quality and length of life,
and this unit of measurement is also well suited to quantifying
comparative effectiveness. In terms of multinational studies, it
seems clear that we need to have absolute measures of effective-
ness by country. Nevertheless, this does not mean that the esti-
mates have to be based on additive models. Absolute estimates of
treatment beneﬁt can be determined by combining relative mea-
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Figure 1 Comparative estimates of effectiveness
quality-adjusted life-years (QALYs) for four differ-
ent regions in theTOwards a Revolution in COPD
Health (TORCH) trial [1]. White circles show
estimates based on splitting the data into four
regions, black diamond shows pooled result over
all regions, crosses show the estimated regional
results based on separate estimation of quality of
life and life expectancy by region, allowing for
different baseline characteristics. Horizontal lines
show 95% conﬁdence intervals. Region codes: US,
United States; EE, Eastern Europe; WE, Western
Europe; Other, all other countries in TORCH
except for Asia Paciﬁc.
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sures with baseline risk estimates from individual countries or
regions, which can adjust for the differences that we know exist
between countries or regions.
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